Related Experiment Videos
Treating benign prostatic hyperplasia with finasteride in Chinese men: one-year experience
1Department of Urology, National Taiwan University Hospital, Taipei, ROC.
Journal of the Formosan Medical Association = Taiwan Yi Zhi
|August 1, 1996
Summary
Finasteride effectively treats symptomatic benign prostatic hyperplasia (BPH) over one year, significantly reducing prostate size and improving urinary flow. Long-term use of finasteride (5 mg/day) demonstrated sustained efficacy with a low incidence of side effects in Chinese men.
Area of Science:
- Urology
- Pharmacology
Background:
- Benign prostatic hyperplasia (BPH) is a common condition in aging men.
- Symptomatic BPH significantly impacts quality of life.
Purpose of the Study:
- To assess the long-term efficacy and safety of finasteride in treating symptomatic BPH.
- Evaluate finasteride's effects on prostate volume, urine flow, symptoms, and PSA levels over 12 months.
Main Methods:
- A 12-month study involving 50 patients with symptomatic BPH.
- Initial 6-month double-blind, placebo-controlled phase followed by a 6-month open-extension phase with finasteride (5 mg/day).
Main Results:
- Significant reductions observed in prostate volume (15%), symptom scores (37%), and PSA levels (1.34 ng/mL).
- Improvement in maximum urine flow rate by 1.9 mL/second.
- Adverse events like decreased libido and impotency were persistent but occurred at a low incidence.
Conclusions:
- Finasteride (5 mg/day) is safe and effective for long-term management of symptomatic BPH in Chinese men.
- Sustained clinical efficacy and a low side-effect profile support its use.